

# **ERA-NET: Aligning national/regional translational cancer research programmes and activities TRANSCAN-2**

**Joint Transnational Call for Proposals 2014 (JTC 2014)  
co-funded by the European Commission/DG Research and Innovation:**

**"Translational research on human tumour heterogeneity to  
overcome recurrence and resistance to therapy"**

---

## **Guidelines for Applicants**

---

### **Submission deadlines**

**Pre-proposals: 16 March 2015 at 16:00 CET**

**Full proposals: 7 July 2015 at 16:00 CEST**

### **Useful links**

Link to: [Electronic proposal submission system](#)  
(Online submission will be possible from 16 February 2015)

For further information, please visit [www.transcanfp7.eu](http://www.transcanfp7.eu)

or

Contact the **Joint Call Secretariat (JCS)** at:

**Ministero della Salute-Istituto Superiore di Sanità,  
Italy**

**E-mail: [transcan-jtc2014@iss.it](mailto:transcan-jtc2014@iss.it)**

**Silvia Paradisi  
Phone: +39 06 4990 6553**

## Background

Under the umbrella of TRANSCAN-2 (ERA-NET for Research Programmes on Translational Cancer Research), 25 funding organisations have agreed to launch a Joint Transnational Call (JTC) in 2014 for collaborative research projects on "**Translational research on human tumour heterogeneity to overcome recurrence and resistance to therapy**". The participating TRANSCAN-2 funding organisations wish to promote innovative interdisciplinary collaboration and truly translational research projects.

The research projects submitted within this call should be based on novel ideas stemming from consolidated previous results and will be endowed with a strong translational research orientation. Project proposals should also clearly demonstrate the potential health impact as well as the added-value of transnational collaboration. The sharing of relevant results, data sets and/or resources within the transnational research consortia is a prerequisite for funding. The research proposals should be built on an effective, multidisciplinary and multi-professional collaboration between academic, clinical, epidemiological or public health research teams and industry. Researchers' exchanges within the consortium are encouraged.

In order to ensure target-oriented projects, the availability of and/or access to clinical biomaterial banks (cells, tissue, blood, DNA, organs, fluids etc.) and the related clinical data of subjects (patient cohorts with comprehensive clinical documentation and characterisation) must be secured and explained. Biomaterial banks must be maintained with "Standard Operation Procedures" (SOPs for extraction, transport, processing, storage and further usage) and previous use and benefit documented by respective publications.

## Proposal submission

TRANSCAN-2 JTC 2014 will be implemented through a two-stage submission procedure: pre-proposals and full proposals. Both pre- and full proposals must be written in English and must be submitted to the Joint Call Secretariat (JCS) by the coordinator of the project through the dedicated electronic submission system exclusively (<http://transcan.cbim.it/>), as PDF files, using the form to be downloaded from the electronic submission system. Original signed versions of either pre- or full proposal are not required. Please note that full proposals will only be accepted from applicants explicitly invited by the JCS to submit them.

Both pre-proposals and full proposals must be submitted to (<http://transcan.cbim.it>) **within the deadlines indicated below.**

**For pre-proposals submission, the system will open on 16 February 2015 at 16:00 (Central European Time, CET).**

**Pre-proposals must be submitted to and received by the JCS no later than 16 March 2015 at 16:00 (Central European Time, CET).**

**For full proposals submission the system will open on 26 May 2015 at 16:00 (Central European Summer Time, CEST).**

**Full proposals must be submitted to and received by the JCS no later than 7 July 2015 at 16:00 (Central European Summer Time, CEST).**

Call deadlines will be strictly enforced and the [electronic system](#) will not allow submissions after call deadlines. Please take into account that the online data entry may be overloaded on the day of the deadline. It is therefore recommended to upload all the required material in due time.

## Eligibility check

Prior to submitting the proposal, applicants should refer to the national/regional eligibility criteria and requirements (Annex 1) and should contact their respective national/regional funding organization contact persons for additional clarification.

***NOTE: An eligibility check before the pre-proposal submission is mandatory for the following funding organization. Please read national/regional regulations (Annex 1) and get in touch with the [national/regional contact points](#):***

- ***The Ministry of Health (MOH), Italy***

The JCS will assess proposals to ensure that they meet the call's formal criteria [e.g. date of submission; number of research groups/countries, type of project partners (academic, clinical/public health and industrial/SMEs), document length, and inclusion of all necessary

information in English. In parallel, the JCS will forward the proposals to the relevant TRANSCAN -2 national/regional funding organizations that will perform a formal check for compliance with their respective eligibility criteria. Proposals passing both checks will be evaluated by independent international scientific experts.

**Please note that after submission of the proposal it is not possible to amend it or to add further documents.**

For additional information, please contact:

**JTC 2014 Joint Call Secretariat (JCS) at  
Ministero della Salute-Istituto Superiore di Sanità, Italy**

E-mail: [transcan-jtc2014@iss.it](mailto:transcan-jtc2014@iss.it)

Silvia Paradisi

**Phone: +39 06 4990 6553**

## Pre-proposal structure

One joint pre-proposal (in English) shall be prepared by the partners and be submitted to the JCS by the project coordinator.

Please note that it is mandatory that the applicants use the pre-proposal application form provided within the electronic submission system (<http://transcan.cbim.it/>), and that the pre-proposal comply with the length indicated for each section. Pre-proposals not complying with these rules will be rejected. The proposal must be written in English and submitted to the JCS by the project coordinator as a PDF file through the [electronic system](#) exclusively.

### **Pre-proposals must include the following information:**

1. Project title and acronym.
2. Project duration.
3. Name and full affiliation of the project coordinator designated by the consortium to act as its representative.
4. Names and full affiliations of the principal investigators (only one per partner).
5. Total requested funding (€).
6. Keywords. Please indicate three to seven keywords representing: the scientific content [(type of cancer; specific aim(s) and topic(s) (see Call Text, chapter 2. Aim of the call)]; the methodological and technological approach(es).
7. Project abstract (max 3,000 characters including spaces).

The abstract should contain:

- a. Background and rationale
- b. Hypothesis
- c. Aims (primary and secondary)
- d. Methods
- e. Expected results and potential impact

8. Adherence of the proposal to the scope, aims and specific topics of the call (see Call Text, chapter 2. Aim of the call). Please, tick box(es).

**Aim 1: Development and validation of methods to investigate human tumour heterogeneity** (including heterogeneity between the primary tumour and the metastatic sites)

- Sampling methods alternative to single biopsy (liquid biopsy, single cell analyses, imaging, etc.) for overcoming tumour sampling bias;
- Methods for assessing tumour heterogeneity, within either the primary tumour or the metastases;
- Methods for tracking tumour evolution along the disease course using minimally- or non-invasive techniques.

**Aim 2: Studies on human tumour heterogeneity in order to guide therapeutic intervention and identify new therapeutic targets**

- Evaluation of the impact of tumour heterogeneity on treatment efficacy and patient outcome (clinical utility of driver/passengers mutations detection, clinical utility of the minor sub-clones identification, clinical utility of the differences in molecular alterations between primary tumour and metastases);
- Development of assays measuring the level of tumour heterogeneity that predicts treatment inefficacy and tumour recurrence;
- Development of assays that define the contribution of tumour heterogeneity in resistance mechanisms and identify new therapeutic targets.

**Aim 3: Development of new precision therapeutic strategies that may prevent human tumour recurrence or resistance to therapy by counteracting tumour heterogeneity**

- Evaluation of treatments (combinations, new strategies, administration scheme) targeting multiple sub-clonal somatic events or preventing resistant sub-clones to emerge.

9. Project description (maximum 20,000 characters including spaces).

This part should contain:

- a. Description of the project rationale, in terms of medical need, and of the present state of the art in the field(s)
- b. Description of the project aims
- c. Statement of the research hypothesis(es)
- d. Preliminary data
- e. Description of methods with specific regards to the study design, the study population(s), intervention/exposure, groups of comparison and expected outcome. Details are also needed regarding the study sample size as defined by *ad hoc* power calculation, and the strategic plan for statistical analysis
- f. Novelty and originality of the project
- g. Feasibility of the project: information about the experience of the research consortium partners in the field; management structure and related implementation plan; added value of the proposed transnational collaboration

- h. Information about the potential impact on cancer recurrence and resistance to therapy with reference to the development, dissemination and use of project results

As annexes, it should contain:

- i. References (one page maximum, as a separate pdf file)
- j. Diagrams, working plan, project schedule (e.g. Gantt chart) and figures (one page maximum, as a separate pdf file)

**10.** Capacity building activities (if eligible for the funding organization / country) (maximum 2,000 characters including spaces).

Please specify whether the project will include capacity building activities. If so, please describe the nature and purpose of the planned activities taking into account information described in the section 2.2 of Call Text. The budget will have to be mentioned in the financial plans (sections 12 and 13) in the appropriate line.

**11.** Brief CV for each partner in the research consortium (i.e. the project coordinator and each principal investigator) including a description of the main domain of research and a list of the five most relevant publications within the last five years regarding the proposal (maximum 4,000 characters including spaces).

**12.** A global financial plan of the project (budget broken down per partner).

**13.** Individual financial plans: a financial plan per partner and budget justification (**Please note that eligibility of costs is subject to national/regional rules and regulations: refer to the Annex 1**).

**14.** Reviewers names (if any) to be excluded from the review of the proposal (up to five). Please note that this information is not compulsory. The CSC will consider these suggestions as it sees fit.

## Full proposal structure

**The information provided in the pre-proposal application is binding for the entire application process. Thus, any substantial changes between the pre-proposal and the full proposal (e.g. title, acronym, composition of the consortia, objectives of the project, etc.) must be communicated in advance to the JCS with detailed justification and will only be allowed by the Call Steering Committee (CSC) under exceptional circumstances.**

Please note that it is mandatory to use the **full proposal application form downloaded from the on-line submission system** (<http://transcan.cbim.it/>) and to comply with the length indicated.

**Full proposals not complying with these rules will be rejected.**

Full proposals must include the following information:

- Project title and acronym.
- Project duration.
- Total requested funding.

- Keywords (3 to 7).
- Publishable project abstract (2,000 characters including spaces, equivalent to about half an A4 page (Please note that if your proposal is selected for funding, the abstract will be published on the TRANSCAN website)).

The abstract should include a concise description of the following:

- a. Background and rationale, i.e. a description of the medical problem and present state of the art in the research field.
  - b. Hypothesis, i.e., the hypothesis/es to be tested
  - c. Aims (primary and secondary), i.e. a description of the study aims either primary or secondary, with a maximum of 3 aims (including both primary and secondary)
  - d. Methods, i.e., a description of the methods applied
  - e. Expected results and potential impact of the research findings on the disease of interest.
- Names and full affiliations of each partner principal investigator.
  - **Project description:** This section represents the scientific “core” of the project. The applicants are requested to provide elements on the study characteristics in a more detailed fashion compared to what previously reported in the homonymous sections of the pre-proposal application form and abstract.
1. **Background and rationale** (maximum 2,000 characters including spaces, equivalent to half an A4 page). Medical needs and present state of the art in the field of interest.
  2. **Specific aims, research hypothesis and preliminary data, experimental design and working plan.** This section should contain:
    - 2.1. Project aims (maximum of 3, either primary or secondary)
    - 2.2. Research hypothesis and supporting data. Supporting (otherwise defined “preliminary”) data are not intended as literature-based evidence, unless such evidence is either authored (i.e., one of the applicants is the first, last and/or corresponding author) or co-authored (i.e., one of the applicants is part of the authorship in any position but the first, last and/or corresponding author) by one or more of the applicants. These data are meant to have been generated by research activities carried out by one or more of the members of the consortium. More specifically, the project under evaluation has to be part of a research pipeline in course of development and the applicants have to exhibit a substantial role within such research pipeline.
    - 2.3. Experimental design, i.e. the strategy that directs researchers towards the study aim(s). Please ensure consistency between each of the project aim and the corresponding experimental design.  
 Experimental Design AIM 1  
 Experimental Design AIM 2 (if applicable)  
 Experimental Design AIM 3 (if applicable).
    - 2.4. Work plan, including a general overview of the entire consortium, and the rationale of the work packages, i.e., one or more subset/s of the entire study tasks assigned to one or more specific partner/s for execution. Task assignment will obey to rules dictated by the specific expertise of the consortium members and the way they complement each other within the study proposed.

2.5 Synthetic description of the work plan at the work package level: please, fill the fields in accordance to the column headings.

**3. Methods, power calculation and statistical analysis, expected outcome and risk analysis** (8,000 characters including spaces, equivalent to about 2 A4 pages).

3.1. Methods: This section should include a detailed description of the study methods. To this aim, details on the following issues are required:

**Study Design:** the applicants are requested to be clear about the type of study being proposed. Most commonly, the proposals will fall into one of the following two main categories i.e., (i) observational study or (ii) intervention trial.

Once the main category has been defined (i.e. observational or intervention study), further elements will help characterize the study design.

If an observational study is proposed, the applicants will be required to add specific details on whether the study is conceived as prospective, retrospective or mixed and whether by design is intended as a cohort, case-control, case-control nested within a cohort or cross-sectional study. For studies with a mixed design, the applicants are requested to be clear about which parts of the study will be retrospective (i.e. based on patient data already collected and stored biological specimens), and which will include patients (and their specimens) to be recruited prospectively; and indicate the number of patients (or samples) in each of these groups.

Since observational studies are particularly prone to confounding and bias, these aspects will have to be carefully considered when designing the study and, later on, carefully addressed in a dedicated section of this application, i.e., section 3.4, namely, "Contingency plan including potential bias, anticipation of problems and possible solutions". Since possible solutions to confounding and bias may derive by an appropriate use of the statistical tools, the applicants may refer to these issues also in the statistical analysis section, i.e., 3.2.

If an intervention trial is proposed, details related to the study design have to be provided regarding the trial phase and type. Such details have to be extended, though not necessarily limited to, the use of randomization (yes/no and specific details on the procedures applied), type of masking (if any), characteristics of the control group/s, parallel group assignment/cross-over. By their nature, randomized clinical trials are less prone to, though not immune, from bias. Actually, the use of randomization procedures, when properly applied, minimizes the chance of selection bias. However, this latter is not the only bias which potentially attempts to the methodological quality of a trial. Again, the issues related to "potential bias, anticipation of problems and possible solutions" have to be considered when defining the study design and specifically addressed in the dedicated section, i.e., section 3.4.

**Study population(s):** Study population(s) should be described exhaustively, i.e., based on clearly stated inclusion and exclusion criteria.

**Intervention/exposure:** Clearly describe the interventions, and how they will be administered to patients within the trial. Please specify the drug dose and mode of administration, and the use of additional intervention(s) if applicable.

**Outcome of interest:** Clearly define all important endpoints (outcome measures), which, in clinical trials, will usually include efficacy, safety (toxicity) and compliance (adherence) to the interventions.

Specific details on the procedural aspects will be added depending on the adherence of the proposal to the specific scopes, aims and topic of the call, as specified in the pre-proposal application, section 8, i.e., "Adherence of the proposal to the scope, aims and specific topics of the call".

If questionnaires will be used (for example to obtain information on lifestyle characteristics), please state whether you will be using established and validated ones, or developing your own.

Details have to be provided regarding the planning for the management and retention of biological samples, specifying whether cooperation with existing or creation of new biobanks is envisaged.

3.2. The proposed sample size has to be clearly supported in terms of power calculation. *Sample size* statements should be clear, unambiguous and capable of being replicated by a reviewer. Therefore, provide all the necessary quantitative information used for the sample size estimate; and make sure that the target sample size and (when relevant) number of events are likely to be achievable in the study time frame. With specific regard to studies with a mixed design, the applicants are required to be clear about which parts of the study will be retrospective (i.e. based on patient data already collected and stored biological specimens), and which would include patients (and their specimens) to be recruited prospectively; and indicate the number of patients (or samples) in each of these groups. If questionnaires will be used (for example to obtain information on lifestyle characteristics), please state whether you will be using established and validated ones, or developing your own. For clinical trials, this section is expected to include referrals to the number of patients to be assessed for eligibility, to be allocated to the trial arms, the expected rate of loss to follow-up. Feasibility of recruitment is a key issue, thus the applicants are requested to provide evidence that the intended recruitment rate is achievable and specify whether and how the collaboration with the partners in the research consortium will facilitate the recruitment. Please specify the plans for monitoring of recruitment and contingency planning for recruitment problems.

It is important that the *statistical analyses* section in the proposal is correct. It is strongly recommended that applicants work closely with colleagues such as medical statisticians or bioinformaticians, who have sufficient knowledge/expertise in study design, i.e. clinical trials and/or observational studies, including studies of prognostic markers (when appropriate). Applicants should be aware that reviewers are likely to take confused statistical statements and incorrect use of terminology as an indication that statisticians have not been involved closely in the planning. The lesson is that genuine, not token, involvement is needed (where a statistician or bioinformatician simply 'approves' the design before submission, without evaluating it carefully). With specific regard to clinical trials, interim analyses and stopping rules have to be anticipated and appropriately motivated. For studies which involve different cancer types or major subtypes, the applicants should consider describing how the different types will be handled in the statistical analyses.

3.3. A referral to the expected outcome has to be included. In specific regard to the intervention trials, this section has to include some justification for the expected treatment outcome.

3.4. This section will be integrated by contingency plan including potential bias, anticipation of problems and possible solutions.

4. **Novelty and originality of the proposal** (1,500-2,000 characters including spaces, equivalent to about half a A4 page). The applicants are requested to underline the importance of their proposals in terms of novelty and originality.
5. **Project feasibility, consortium governance and management of project coordination** (5,000 characters including spaces, equivalent to about 1 A4 page). This section should include:
  - 5.1. A Description of the infrastructures and resources relevant to the implementation of the work plan, concept of data and material acquisition and storage, availability of biological resources, data management and elaboration.
  - 5.2. A Description of the research consortium governance and management as well as of project coordination. This should include: i) a description of the governance and management structure and of project coordination planning (meeting, monitoring, etc.); ii) an outline of responsibilities and project effort (expressed in person months) of each participating research group per work package;
6. **Potential impact on cancer recurrence and resistance to therapy in reference to the development, dissemination and use of the project results** (2,500-3,000 characters including spaces, equivalent to about  $\frac{3}{4}$  of an A4 page)
7. **References** (4,000 characters including spaces, equivalent to about 1 A4 page).
8. **Timeline and milestones** (2,000-2,500 characters including spaces, equivalent to about half an A4 page). This section should include a graphic representation of the project time plan and the milestones (Gantt chart) on a 12-month basis, that is, at 12, 24 and 36 months.
9. **Diagram** which compiles the work plan, the contribution of the partners to each work package and their interactions (Pert diagram).
10. **Added value of the collaboration in the proposed transnational project** (2,000 characters including spaces, equivalent to about half an A4 page). This section should describe the quality of the transnational research consortium, illustrating:

- i) the level of expertise of the individual partner research teams in the field(s) of the proposal (team scientific track record, publications, patents, etc.)
  - ii) the quality of the collaboration between the research teams and added value of the research consortium with respect to the individual team.
11. **Description of past and ongoing research projects** of each participating group related to the present topic: specify in the table the funding sources (include at least: title, ID number, amount and duration of funded project, correlation to the requested proposal, funding agency).
  12. **Description of existing or potential patents** (own or third party) and present/future position with regard to intellectual property rights, both within and outside the consortium (i.e. freedom to operate, barriers to sharing materials or results), if applicable (2,500 characters including spaces, equivalent to about half an A4 page).
  13. **Ethical and legal issues.** Ethical and legal issues, according to national/regional regulations, if applicable (e.g. informed consent, data protection, material transfer obligations, use of animals) (max. ½ page).
  14. **Brief CVs for each research partner** (i.e., the project coordinator and each principal investigator) including a description of the main domain of research and a list of the five most relevant publications within the last five years, demonstrating the competence to carry out the project (4,000 characters including spaces, equivalent to about 1 A4 page).
  15. **Capacity building activities (optional section)** (4,000 characters including spaces, equivalent to about 1 A4 page):
    - a) Description of capacity building activities and relevance to the objectives of the proposal;
    - b) Description of the involved candidate [CV, background (scientific, medical, etc.); scientific production; current work; coherence of the training with the CV,];
    - c) Description of the host team (expertise in the field, qualification in research of the responsible person);
    - d) Justification of the additional separate budget needed for these specific activities.
  16. **Clinical Trial Description (if applicable):** trial synopsis and flow diagram.
  17. **Global financial plan** (whole budget broken down per year and per partner). Please follow regional/regional rules and regulations on the eligibility of costs.
  18. **Individual financial plans** for each partner and budget justification. Please note that eligibility of costs is subject to national rules and regulations: refer to the Annex 1.
  19. **Signatures** of the project coordinator and all project partners principal investigators (signed PDF) declaring they keep track record of evidence that each of their respective team members agreed to participate in the proposal submitted. Please note: All the scanned signature pages should be assembled in a single PDF file to be uploaded as an annex pdf.

Please note that additional information may be requested by national/regional funding organisations, in accordance with their respective eligibility criteria.

**Important reminders for all applicants**

Applicants should refer to the national/regional eligibility criteria and requirements (Annex 1) and should contact their respective [national/regional funding organisation contact persons](#) prior to submitting the application. An **eligibility check** is mandatory for some national/regional funding organizations before the submission deadline (see above).

The JCS will assess proposals to ensure that they meet the call's formal criteria [e.g. date of submission; number of participating research groups, type of project partners (academic, clinical/public health and industrial/SMEs), and inclusion of all necessary information in English, document length]. In parallel, the JCS will forward the proposals to the relevant TRANSCAN national/regional funding organisations that will perform a formal check of compliance with their respective eligibility criteria. Proposals passing both checks will be forwarded to independent international scientific experts for evaluation.

Please note that once the JTC 2014 is closed it is not possible to amend an application or add additional documents.

## Start of the project and Consortium Agreement

In order to ensure a proper conduct of the project activities, a Consortium agreement (CA) should be signed between the partners before the official start date of the project. The CA should address the following issues: governance structure and decision making process, responsibilities between the partners and subsequent liability, reporting, ownership and use of research results, IPR, publications, confidentiality. Upon request, copy of the CA will be communicated to the concerned TRANSCAN-2 JTC 2014 funding organizations.

Consortium partners of projects selected for funding will decide between them on a common start date for the project, which would be the reference date for yearly and final reports and extensions. The official start date shall be communicated by the project coordinator to the JCS and shall appear in the consortium agreement.

## ANNEX 1. NATIONAL/REGIONAL REGULATIONS AND CONTACT INFORMATION

<b>Country</b>	<b>AUSTRIA</b>
<b>Funding organisation</b>	Fonds zur Förderung der Wissenschaftlichen Forschung (FWF) / Austrian Science Fund <a href="http://www.fwf.ac.at">http://www.fwf.ac.at</a>
<b>National contact persons</b>	<b>Dr. Stephanie RESCH</b> Austrian Science Fund Haus der Forschung, Sensengasse 1 1090 Vienna, Austria Tel: +43-1-505 67 40-8201 E-mail: <a href="mailto:stephanie.resch@fwf.ac.at">stephanie.resch@fwf.ac.at</a>
<b>National programme</b>	
<b>Funding commitment</b>	0.75 Mio. €
<b>Anticipated number of fundable project partners</b>	3
<b>Maximum funding per grant awarded to a project partner</b>	no limit / amount of typical (sub)projects: ~0.3 Mio. €
<b>Eligibility of projects</b>	joint research projects
<b>Eligibility of a partner as a beneficiary institution</b>	
<b>Eligibility of principal investigator or other research team member</b>	individual researcher or teams of researchers, working in any kind of nonprofit organization: e.g. University, University hospital, Non-university research institute <i>Please refer also to the general FWF Funding Guidelines:</i>
<b>Eligibility of costs, types and their caps</b>	Personnel, Consumables, Animals, Subcontracts, Equipment, Travel, Documentation (Note: publication costs are handled according to FWF stand-alone projects) <i>Please refer also to the general FWF Funding Guidelines:</i> <a href="http://www.fwf.ac.at/en/research-funding/application/international-programmes/joint-projects-era-nets/">http://www.fwf.ac.at/en/research-funding/application/international-programmes/joint-projects-era-nets/</a>
<b>National phase</b>	Only Proposals reaching 2 <sup>nd</sup> stage (full proposal) of the call: PI has to submit <b>one-page project summary</b> in English and in German, <b>application forms</b> (application form, itemization of requested funding and forms for international research partners) and <b>justification</b> for the costs.
<b>Further guidance</b>	

<b>Country</b>	<b>BELGIUM: FLANDERS</b>
<b>Funding organisation</b>	Research Foundation – Flanders (FWO) <a href="http://www.fwo.be/">http://www.fwo.be/</a>
<b>National contact persons</b>	<p><b>Dr. Olivier BOEHME</b> Senior Science Administrator Research Foundation - Flanders Egmonstraat 5 B-1000 Brussels, Belgium Tel. +32 2 550 15 45 E-mail: <a href="mailto:eranet@fwo.be">eranet@fwo.be</a></p> <p><b>Toon MONBALIU</b> Advisor Research Affairs Tel. +32 2 550 15 70 E-mail: <a href="mailto:eranet@fwo.be">eranet@fwo.be</a></p>
<b>National programme</b>	New Research Projects
<b>Funding commitment</b>	€ 200.000
<b>Anticipated number of fundable project partners</b>	1
<b>Maximum funding per grant awarded to a project partner</b>	€ 200.000
<b>Eligibility of projects</b>	<p>Art. 9 of the FWO-regulation on the regular research projects is applicable. In this article is stated who can apply as a Principal Investigator for a research project:</p> <ul style="list-style-type: none"> <li>- an Independent Academic Staff (ZAP) member with an appointment of more than 10% at a Flemish university;</li> <li>- an Independent Academic Staff member with an appointment of 10% at a Flemish university and whose main task is research;</li> <li>- an Independent Academic Staff member with an appointment of 5% at a Flemish university and with an appointment as (assistant) clinical head or an equal function in a university hospital;</li> <li>- an academic staff member with an appointment at the Evangelical Protestant Faculty in Leuven and the Faculty for Protestant Theology in Brussels;</li> <li>- a research director of the FWO;</li> <li>- a designated beneficiary of an ERC Starting Grant, an ERC Advanced Grant or an Odysseus II grant, with a Flemish university as a host institution.</li> </ul> <p>If more than one university is involved in the project, at least one promoter of each university has to fulfill the above mentioned eligibility</p>

	<p>criteria as well as to occupy a position covering entirely the period of the project that is applied for.</p> <p>The criteria have to be met with at the start of the project at the latest, which has to be proven at the date of the submission.</p> <p>If more than one universities are involved in the project, at least one promoter or co-promoter of each university has to fulfill the above mentioned eligibility criteria as well as to occupy a position covering entirely the period of the project that is applied for.</p> <p>The criteria have to be met with at the start of the project at the latest, which has to be proven at the date of the submission.</p>
<b>Eligibility of a partner as a beneficiary institution</b>	Universities in the Flemish Community. If the research is conducted in collaboration with a non-university institute, it shall be carried out under the supervision and responsibility of a Flemish university.
<b>Eligibility of principal investigator or other research team member</b>	See under 'Eligibility of projects'.
<b>Eligibility of costs, types and their caps</b>	<p>Staff:</p> <ul style="list-style-type: none"> <li>- staff costs of scientific or technical employees</li> </ul> <p>Consumables:</p> <ul style="list-style-type: none"> <li>- fees for job students, pollsters and expenses resulting from the invitation of a guest researcher in the research department;</li> <li>- small equipment of less than €20,000 per unit, required for the project;</li> <li>- fees for student stays and participation in conferences abroad provided they are in line with the awarded research project;</li> <li>- access to and dissemination of research results;</li> <li>- travel costs in Belgium.</li> </ul> <p>Equipment</p>
<b>National phase</b>	The FWO-funding scheme for regular research projects is opened up once a year.
<b>Further guidance</b>	

<b>Country</b>	<b>BELGIUM: FRENCH SPEAKING COMMUNITY</b>
<b>Funding organisation</b>	Fund for Scientific Research (FNRS)
<b>National contact persons</b>	<b>Dr. Arnaud GOOLAERTS</b> Scientific Officer FRS-FNRS Rue d'Egmont 5 B-1000 Brussels Belgium Tel. +32 2 504 93 28 E-mail: <a href="mailto:arnaud.goolaerts@frs-fnrs.be">arnaud.goolaerts@frs-fnrs.be</a>
<b>National programme</b>	Projets de Recherche - PDR
<b>Funding commitment</b>	0.200 Mio. €
<b>Anticipated number of fundable project partners</b>	1
<b>Maximum funding per grant awarded to a project partner</b>	
<b>Eligibility of projects</b>	Basic research (low Technology Readiness Level) carried out in a research institution from the "Fédération Wallonie-Bruxelles" The FNRS will not fund industrial partners or any activity related to the private sector.
<b>Eligibility of a partner as a beneficiary institution</b>	The applicant must be affiliated to a research institution from the Fédération Wallonie-Bruxelles. The applicant should also: be a permanent researcher of F.R.S. - FNRS (Chercheur qualifié, Maître de recherches or Directeur de recherches), or hold a tenure track position (or an assimilated position including pending tenure track) within a research institution from the Fédération Wallonie-Bruxelles, or be a permanent research staff member in the 'Ecole Royale Militaire', or be a permanent research staff member of a federal scientific institution in which case he can act as a co-promotor only.  The applicant should not have reached retirement at the starting date of the project. If the applicant reaches the age of retirement in the course of the project, he should precisely describe in the proposal how the handover will be managed.
<b>Eligibility of principal investigator or other research team member</b>	See: <a href="http://www.ncp.frs-fnrs.be/index.php/17-appels/131-fnrs-eligibility-criteria-transcan-2014">http://www.ncp.frs-fnrs.be/index.php/17-appels/131-fnrs-eligibility-criteria-transcan-2014</a>

<p><b>Eligibility of costs, types and their caps</b></p>	<p>The maximum amount allocated per project is <b>200.000 EUR</b>. The following costs are eligible:</p> <p><b>Personnel:</b></p> <p>Scientifique doctorant € 36.400/year          Scientifique non postdoctoral € 62.000/year          Scientifique postdoctoral € 72.300/year          Technicien € 52.600 (full time/year) - € 26.600 (half time/year)          Chercheur temporaire postdoctoral € 46.600/year</p> <p>The categories « scientifique doctorant » and « chercheur temporaire postdoctoral » can only be Full time positions. The category « vétérinaire clinicien-chercheur spécialiste » is a part-time position. The three other positions can be filled in either Full time or part-time.</p> <p>The usual duration of ERA-NET research programmes is three years. However, when the project involves a PhD student, the principal investigator can apply for an additional one year funding in order to complete the four years PhD programme. This request should be submitted to F.R.S.-FNRS six months before the end of the project, together with the written agreement from the "Comité d'accompagnement".</p> <p><b>Equipment (max. 30.000 EUR/year)</b></p> <p><b>Running costs: (max. 15.000 EUR/year):</b> travel expenses; organisation of small scientific events in Belgium; consumables and the following support costs: Conception d'ouvrage, Réalisation de dictionnaire, Achat de livre, Encodage, Location de licence de logiciel, Inscription à un congrès, Ordinateur, Scannage</p> <p>"Overhead" is not an eligible cost. If the project is selected for funding, these costs will be subject to a separate agreement between the institution of the beneficiary and the F.R.S.-FNRS. General rules and regulations of FNRS apply: <a href="http://www.frs-fnrs.be">www.frs-fnrs.be</a></p>
<p><b>National phase</b></p>	
<p><b>Further guidance</b></p>	<p>See: <a href="http://www.ncp.frs-fnrs.be/index.php/17-appels/131-fnrs-eligibility-criteria-transcan-2014">http://www.ncp.frs-fnrs.be/index.php/17-appels/131-fnrs-eligibility-criteria-transcan-2014</a></p>

<b>Country</b>	<b>ESTONIA</b>
<b>Funding organisation</b>	Estonian Research Council (ETAg) <a href="http://www.">http://www.</a>
<b>National contact persons</b>	<p><b>Mr Argo SOON</b> Estonian Research Council Soola 8 51013 Tartu Estonia Tel: +372 7300 372 E-mail: <a href="mailto:argo.soon@etag.ee">argo.soon@etag.ee</a></p> <p><b>Mr Aare IGNAT</b> Estonian Research Council Tel: +372 731 7364 E-mail: <a href="mailto:aare.ignat@etag.ee">aare.ignat@etag.ee</a></p>
<b>National programme</b>	
<b>Funding commitment</b>	0.100 Mio. €
<b>Anticipated number of fundable project partners</b>	2
<b>Maximum funding per grant awarded to a project partner</b>	50 000 €
<b>Eligibility of projects</b>	According to call text
<b>Eligibility of a partner as a beneficiary institution</b>	Legal bodies such as universities, research institutions, enterprises, NGOs and other, provided availability of research staff that meets eligibility criteria described below.
<b>Eligibility of principal investigator or other research team member</b>	<ol style="list-style-type: none"> <li>1. The Principal Investigator <ol style="list-style-type: none"> <li>1.1. Principal Investigator is the applicant of the grant, to whom the grant has been allocated within an open competition and who shall be responsible for the use of the grant for specified purpose and for the productive realisation of the grant project. The Council shall enter into a grant agreement with the Principal Investigator</li> <li>1.2. Has as a rule entered into an employment relationship with the legal person (hereinafter Institution), which is the basis of the realisation of the grant project and through which the grant shall be allocated to the Principal Investigator</li> <li>1.3. Must be a holder of the doctoral degree of Estonia or an equivalent academic degree (both awarded by the deadline of submission of the grant application, at the latest).</li> <li>1.4. Must have published within the last five years prior to the proposal's submission deadline at least three publications, which comply with the requirements of clauses 1.1 of the classification of publications of the Estonian Research Information System (ETIS), or at least five public ations, which comply with the requirements of clauses 1.1, 1.2, 2.1 and 3.1 of the classification of publications of</li> </ol> </li> </ol>

	<p>the ETIS; the monographs are equalised to each author with three publications mentioned in clause 1.1 if the number of its authors is three or less. If the applicant has been on the parental leave or in the compulsory military service within these last five years, the deadline of the publication requirement shall be extended by the time stayed on the parental leave or compulsory military service.</p> <p>2. The main participant of the project</p> <p>2.1. The main participant of the project is a person who participates in the substantial performance of the project.</p> <p>2.2. The main participant of the project shall either possess at least the master's degree or the respective qualification and must have published at least one publication within the last three years prior to the proposal's submission deadline, which comply with the requirements of clauses 1.1, 1.2, 2.1 or 3.1 of the classification of publications of the ETIS; or be a doctoral candidate.</p>
<p><b>Eligibility of costs, types and their caps</b></p>	<p>3. A budget of proposal shall consist of the research expenses and the overhead costs of the institution, through which the grant project is to be carried out.</p> <p>4. The research expenses consist of personnel costs (incl. scholarships), travel costs, other direct costs and subcontracting costs. The expenses on research are clearly required to carry out the project and respectively identifiable.</p> <p>5. Remuneration may be only paid out of the grant to the Principal Investigator, main participants in the project and auxiliary staff according to the time they participate in the grant project and their total salary cost for Institution (comprising basic monthly salary plus social security charges and other statutory costs). Double funding of activities already have contributions is not acceptable.</p> <p>6. Scholarship equal to the state grant may be paid out of the grant to doctoral and master's candidates not paid any salary by Institution. The scholarship for a master's candidate may not exceed 300 euros and for a doctoral candidate 400 euros a month. The scholarship of the doctoral candidate along with the State education allowance may not exceed 600 euros a month. Should a doctoral or master's candidate participate in several projects financed by the Council, the total amount of the scholarship received from different projects may not exceed the aforementioned amounts. It means that maximum of the scholarships per doctoral candidate and master's candidates are respectively annually 4800 euros and 3600 euros.</p> <p>7. Travel costs cover expenses for transport, accommodation and daily allowances (except in case of internal travel).</p> <p>8. Subcontracting costs cover generally only additional or complementary tasks (e.g. costs for translation, analyses, etc.) to the third parties. Core project research tasks should not be subcontracted.</p> <p>9. Other direct costs are:</p> <p>9.1. Consumables related to the project</p> <p>9.2. Costs for publishing and dissemination of project results (fair distribution of costs between partner should be followed);</p> <p>9.3. Costs for organising the meetings/seminars/conferences (only in Estonia)</p> <p>9.4. Fees for participating in scientific forums and conferences;</p> <p>9.5. All other costs which are clearly required for the implementation of the project and respectively identifiable.</p> <p>10. Overhead costs of the institution must not exceed a maximum of 20% of eligible direct costs and should be cover general expenses of the institution.</p> <p>11. Participants' personal expenses or expenses not directly related to the project are not eligible, including costs for equipment and services</p>

	intended for public use (copying machine or printer publicly used, phone bills, copying service, etc.). Such expenses shall be covered from the overhead fee
<b>National phase</b>	<p>The grant will be awarded if:</p> <ul style="list-style-type: none"> <li>• the submitted project proposal of the partner of Estonia is in accordance with the criteria at the present document;</li> <li>• the submitted project proposal is selected for the award by the TRANSCAN Call Steering Committee;</li> <li>• the project Consortium Agreement is signed.</li> </ul> <p>The decision will be made by the Estonian Research Council on the base of the project ranking list by the TRANSCAN Call Steering Committee. The available budget will be taken into account.</p>
<b>Further guidance</b>	<p>Estonian Research Council funds basic and applied research in terms of Organisation of Research and Development Act.</p> <p>Proposals may be submitted by the Estonia based research and development institutions in terms of Organisation of Research and Development Act.</p>

<b>Country</b>	<b>FRANCE</b>	
<b>Funding organisations</b>	<a href="#">National Cancer Institute (INCa)</a>	<a href="#">ARC Foundation for Cancer Research (Foundation ARC)</a>
<b>National contact persons</b>	<p><b>For INCa:</b></p> <p><b>Estelle GERBAUD, PharmD</b>  <b>Research and Innovation Division</b>  52 avenue André Morizet  92513 Boulogne Billancourt Cedex  Email : <a href="mailto:egerbaud@institutcancer.fr">egerbaud@institutcancer.fr</a>  Phone: + 33 (0)1 41 10 14 16</p>	<p><b>For ARC Foundation:</b></p> <p><b>Nancy ABOU-ZEID, PhD</b>  <b>Translational Research &amp; Innovation</b>  Fondation ARC pour la recherche sur le cancer  9 Rue Guy Moquet – BP 90003  94803 Villejuif Cedex, France  Tel : +33 (0)1 45 59 58 44  E-mail: <a href="mailto:nabou-zeid@fondation-arc.org">nabou-zeid@fondation-arc.org</a></p>
<b>National programme</b>	French National Cancer Plan 2014-2019	
<b>Funding commitment</b>	INCa: 1.5M euro	ARC Foundation: 0.5M euro
<b>Anticipated number of fundable project partners</b>	INCa : From 5 to 10 research teams	ARC Foundation: From 1 to 3 research teams
<b>Maximum funding per grant awarded to a project partner</b>	INCa and ARC Foundation do not have a maximum funding per grant; the amount depends on the scientific and medical needs and should be justified in the requested budget.	
<b>Eligibility of projects</b>	Please refer to the call text	
<b>Eligibility of a partner as a beneficiary institution</b>	<ul style="list-style-type: none"> <li>- Public research institutions (university, EPST, EPIC, etc.)</li> <li>- Non-profit organisations (associations, foundations, etc.)</li> <li>- Hospitals or other health care providers (CHU, CRLCC, etc.)</li> </ul>	
<b>Eligibility of principal investigator or other research team member</b>	<p><i>Reminder: Each transnational consortium must nominate a coordinator from one of the JTC 2014 countries/region. The coordinator will be responsible for the internal scientific management and for the external representation towards the JCS and the CSC. Each consortium partner will be represented by one principal investigator, who will be the contact person for the respective national/regional funding organization.</i></p> <ul style="list-style-type: none"> <li>- Public research institutions (university, EPST, EPIC, etc.)</li> <li>- Non-profit organisations (associations, foundations, etc.)</li> <li>- Hospitals or other health care providers (CHU, CRLCC, etc.)</li> </ul> <p><i>Please note that for the reason that a personal investment is necessary for the good progress of the project, the PI is not allowed to coordinate simultaneously more than 3 projects funded by INCa.</i></p>	
<b>Eligibility of costs, types Eligibility of costs, types and their caps</b>	<p><b>For the research project:</b></p> <ul style="list-style-type: none"> <li>- <u>Equipment</u>: up to 150 000 € including taxes per equipment; the total amount of the “equipment” expenses could not exceed a maximum of 30% of the total grant awarded</li> </ul>	

	<ul style="list-style-type: none"> <li>- <u>Consumables and subcontracting</u></li> <li>- <u>Personnel costs</u> <ul style="list-style-type: none"> <li>• Salary costs for permanent staff may be included in the budget with the exception of civil servants</li> <li>• Please note that salary for PhD student may only be included in the 'capacity building and training activities' component (see below).</li> </ul> </li> <li>- <u>Travel and accommodation</u>: only for the partner team members and for project management meetings; the total amount of the "Travel and accommodation" expenses could not exceed a maximum of 8% of the total grant awarded (Travel and accommodation costs to attend the intermediate and/or final TRANSCAN status symposium as specified in the Call text could be included in addition to the 8%)</li> <li>- <u>Indirect costs/overheads</u>: not eligible</li> </ul> <p><b>For the capacity building and training activities:</b></p> <ul style="list-style-type: none"> <li>- Salary costs for support staff (technician, engineer, etc)</li> <li>- Salary for scientist, physician, veterinarian or pharmacist (short term training, PhD student, post-doctoral fellowship)</li> <li>- Travel and accommodation for exchanges programme</li> </ul> <p>Costs for project management workshops and dissemination events such as symposium are not eligible</p>
<b>National phase</b>	Not required. Only the submission of the joint proposal is required.
<b>Further guidance</b>	Not applicable

<b>Country</b>	<b>GERMANY</b>
<b>Funding organisation</b>	German Federal Ministry for Education and Research (BMBF) <a href="http://www.gesundheitsforschung-bmbf.de">www.gesundheitsforschung-bmbf.de</a>
<b>National contact persons</b>	<p><b>Dr. Akin Akkoyun</b> Tel.: +49 (0)228 3821-1864; Akin.Akkoyun@DLR.de</p> <p><b>Dr. Falko Drews</b> Tel.: +49 (0)228 3821-1742; Falko.Drews@DLR.de</p> <p><b>Dr. Hubert Misslisch</b> Tel.: +49 (0)228 3821-1271; Hubert.Misslisch@DLR.de</p> <p><b>Project Management Agency of the German Aerospace Centre</b> (PT-DLR) - Health Research Heinrich-Konen-Str. 1 D-53227 Bonn, Germany Tel: +49 (0)228/3821-1210</p>
<b>National programme</b>	Framework Programme "Health Research" of the Federal Government
<b>Funding commitment</b>	3 Mio. €
<b>Anticipated number of fundable project partners</b>	12 – 15 research groups
<b>Maximum funding per grant awarded to a project partner</b>	No limit, but respect the available budget and anticipated number of fundable research groups.
<b>Eligibility of projects</b>	-
<b>Eligibility of a partner as a beneficiary institution</b>	Legal body: university, university hospital, non-university public research institute, industry (note: industry is funded with a maximum of 50%-60% of the total project cost)
<b>Eligibility of principal investigator or other research team member</b>	-

<b>Eligibility of costs, types and their caps</b>	Personnel, consumables, animals, subcontracts, equipment, travels, capacity building costs (all according to national regulations).
<b>National phase</b>	After the joint TRANSCAN JTC 2014 peer review has been completed and the final (scientific) ranking list has been performed and endorsed by the Call Steering Committee, PT-DLR will invite those principal investigators to be funded to enter the formal national negotiations. That is, a formal proposal (written in German) must be submitted, which will formally be granted after an administrative and scientific processing (according to national regulations).
<b>Further guidance</b>	<a href="http://www.gesundheitsforschung-bmbf.de/de/5442.php">http://www.gesundheitsforschung-bmbf.de/de/5442.php</a>

<b>Country</b>	<b>GREECE</b>
<b>Funding organisation</b>	General Secretariat for Research and Technology, Ministry of Education and Religious Affairs (GSRT) <a href="http://www.gsrt.gr">http://www.gsrt.gr</a>
<b>National contact persons</b>	Ministry of Education & Religious Affairs General Secretariat for Research & Technology International S&T Cooperation Directorate-European Union Division 14-18 Messogion Ave., 11527 Athens, Greece  <b>Danae FARMAKI</b> Email: <a href="mailto:d.farmaki@gsrt.gr">d.farmaki@gsrt.gr</a>  Tel.: (+30) 210 7458100
<b>National programme</b>	Strategic Plan for the Development of Research, Technology and Innovation 2007-2013, European S&T Cooperation-ERANETS Joint Transnational Calls
<b>Funding commitment</b>	0.5 Mio €
<b>Anticipated number of fundable project partners</b>	5
<b>Maximum funding per grant awarded to a project partner</b>	
<b>Eligibility of projects</b>	joint research projects
<b>Eligibility of a partner as a beneficiary institution</b>	Higher Education Institutions, Research Centres, Public entities, Enterprises (private sector entities are funded up to 70% of their budget depending on their size and kind of research).
<b>Eligibility of principal investigator or other research team member</b>	Personnel costs are costs for scientific and administrative personnel, for researchers with employment contracts as well as for other supporting staff (temporary employees etc.) as they are employed on the research project.
<b>Eligibility of costs, types and their caps</b>	personnel cost, consumables, equipment, sub-contracting (provided that it is justified), dissemination and exploitation of results, travelling connected to the project, additional costs up to 5% of the total budget (see relevant "Guide for applicants", <a href="http://www.gsrt.gr">www.gsrt.gr</a> )
<b>National phase</b>	
<b>Further guidance</b>	

<b>Country</b>	<b>ISRAEL</b>
<b>Funding organisation</b>	CSO-MOH <a href="http://www.health.gov.il/Subjects/research/Pages/Research-Foundation.aspx">http://www.health.gov.il/Subjects/research/Pages/Research-Foundation.aspx</a>
<b>National contact persons</b>	<b>Dr. Ami BEN-YEHUDAH</b> The Medical Research Administration Chief Scientist Office Israeli Ministry of Health 39, Yirmiyahu St. Jerusalem 91010, Israel Tel: +972-2-5082613  E-mail: <a href="mailto:ahmi.by@moh.health.gov.il">ahmi.by@moh.health.gov.il</a>
<b>National programme</b>	Medical Research Administration
<b>Funding commitment</b>	Up to 0.20 Mio €
<b>Anticipated number of fundable project partners</b>	Up to 2
<b>Maximum funding per grant awarded to a project partner</b>	Up to 100,000 €
<b>Eligibility of projects</b>	Bio-Medical research at large
<b>Eligibility of a partner as a beneficiary institution</b>	<b>Research institutes in Israel</b>
<b>Eligibility of principal investigator or other research team member</b>	PhD, MD or equivalent
<b>Eligibility of costs, types and their caps</b>	Consumables, personnel (excluding PI and Co-PI), animals, travel (ERA-Net related only), overhead, NO training costs
<b>National phase</b>	all applicants must contact Dr. Ben-Yehudah <b>before</b> submitting the proposal. Not contacting CSO-MOH before submission might result in declaring the proposals as not eligible.
<b>Further guidance</b>	

<b>Country</b>	<b>ITALY</b>
<b>Funding organisation</b>	Ministry of Health (Ministero della Salute) <a href="http://www.salute.gov.it">www.salute.gov.it</a>
<b>National contact persons</b>	<p><b>Dr. Silvia PARADISI</b> phone: +39 064990 6553.</p> <p><b>Dr. Maria FERRANTINI</b> phone: +39 065994.2684</p> <p><b>Dr. Tiziana CATENA</b> phone: +39 065994.3528</p> <p>Office of Health Research, Directorate General for Health Research and Innovation Ministry of Health, Viale Giorgio Ribotta, 5. 00144 Rome, Italy E-mail: <a href="mailto:transcan@sanita.it">transcan@sanita.it</a></p>
<b>National programme</b>	Framework National Programme "Health Research" of the Ministry of Health.
<b>Funding commitment</b>	About 3 Mio. €
<b>Anticipated number of fundable project partners</b>	10-15
<b>Maximum funding per grant awarded to a project partner</b>	~ 0.25 M€
<b>Eligibility of projects duration</b>	Max 3 years
<b>Eligibility of a partner as a beneficiary institution</b>	<p><b>On the basis of the D.Lgs 229/99:</b></p> <ol style="list-style-type: none"> <li>Scientific Institute for Research, Hospitalization and Health Care (Istituti di Ricovero e Cura a Carattere Scientifico pubblici e privati, IRCCS).</li> </ol> <p><b>Non fundable:</b> University, other research institute; Company</p>
<b>Eligibility of principal investigator or other research team member</b>	In order to expedite the eligibility check process, the Ministry of Health will grant an eligibility clearance to the applicants prior to the submission of the pre-proposals. To this end, it is mandatory that the applicants fill out and return a <a href="#">pre-eligibility check form</a> before submitting their pre-proposals to the Joint Call Secretariat. It is strongly recommended that the form, completed and duly signed, is returned at least 10 working days before the pre-proposal submission deadline. Applicants will be sent a written notification of their eligibility status. The simultaneous participation in proposals submitted in 2015 to different transnational research calls, funded by the Ministero della Salute, is not allowed to Italian Principal Investigators or other research team members.

<p><b>Eligibility of costs, types and their caps</b></p>	<p>Only costs generated during the lifetime of the project can be eligible.          Personnel (only temporary contracts) (max 50%); Consumables; Animals; Subcontracts (Max 20%); Equipment (only on hire); Travel (max 10%); Overhead (max 10%); Documentation (Max 1%); (all according to national regulations).          Travel expenses and subsistence allowances associated with training activities linked to the project.</p>
<p><b>National phase</b></p>	<p>After the joint TRANSCAN JTC 2014 peer review has been completed and the final (scientific) ranking list has been performed and endorsed by the Call Steering Committee, the Ministry of Health will invite the principal investigators of the projects approved for funding to enter the formal national negotiations (according to national regulations).          Submission of annual scientific and financial reports at the national level will be required according to the rules of the Ministry of Health.</p>
<p><b>Further guidance</b></p>	<p>Further information on the rules of the Ministry of Health can be found at <a href="http://www.salute.gov.it">www.salute.gov.it</a>, section "Ricerca Sanitaria", or requested to the national contact persons.</p>

<b>Country</b>	<b>ITALY</b>
<b>Funding organisation</b>	Ministry of Education, Universities and Research (MIUR) <a href="http://www.ricercainternazionale.miur.it">http://www.ricercainternazionale.miur.it</a>
<b>National contact persons</b>	<p><b>Dr. Alessandra CUSCIANNA</b> Office for European Research, MIUR Piazzale Kennedy, 20 - 00144 Roma Phone: +39 0697726469 E-mail: <a href="mailto:alessandra.cuscianna@miur.it">alessandra.cuscianna@miur.it</a></p> <p><b>Mrs. Irene GUGLIELMO</b> Office for Research and Enterprises, MIUR Piazzale Kennedy, 20 - 00144 Roma Phone:+39 0697727470 E-mail: <a href="mailto:irene.guglielmo@miur.it">irene.guglielmo@miur.it</a></p>
<b>National programme</b>	FIRST
<b>Funding commitment</b>	0.5Mio. € as grants and 0.5 Mio € as loans
<b>Anticipated number of fundable project partners</b>	No prescriptions
<b>Maximum funding per grant awarded to a project partner</b>	No prescriptions
<b>Eligibility of projects</b>	No prescriptions
<b>Eligibility of a partner as a beneficiary institution</b>	<p>According to art. 60 of the Decree-Law n. 83/2012 and art. 4 of its implementing Ministerial decree 115/2013, the following entities are eligible, providing that they have stable organization in Italy:</p> <ul style="list-style-type: none"> <li>▪ Enterprises and private research centres or organizations</li> <li>▪ Universities and public research centres or organizations</li> <li>▪ Research institutions or research organizations, associations or foundations which perform mainly research activities as stated in their statutory documents.</li> </ul>
<b>Eligibility of principal investigator or other research team member</b>	No prescriptions
<b>Eligibility of costs, types and their caps</b>	All costs incurred during the lifetime of the project under the following categories are eligible: Personnel, Equipment, Subcontracting, Consumables, Dissemination and Coordination activities, and Overheads.

<b>National phase</b>	All Italian participants must send to MIUR a set of additional national documents as defined in the “Avviso integrativo nazionale”. Any participant who does not send its national documents by the pre-proposal deadline, will be considered ineligible
<b>Further guidance</b>	The criteria and provisions provided herewith are intended only for informative purposes. The complete list of criteria and provisions legally valid, which must be respected by all the Italian participants, as well as the additional forms to be filled in and to be sent to MIUR by the JPco-fuND deadline, are included in the “Avviso integrativo nazionale”, published on MIUR website ( <a href="http://www.ricercainternazionale.miur.it">http://www.ricercainternazionale.miur.it</a> ) and in the applicable Italian laws.

<b>Country</b>	<b>ITALY</b>
<b>Funding organisation</b>	Alliance Against Cancer (ACC) <a href="http://www.t">http://www.t</a>
<b>National contact persons</b>	<p><b>Dr. Ruggero DE MARIA</b> Tel: +39 065994.3412 Email: demariaruggero@gmail.com</p> <p><b>Dr. Gennaro CILIBERTO</b> Tel: +39 065994.3412 Email: g.ciliberto@istitutotumori.na.it</p> <p><b>Dr. Maddalena BARBA</b> Tel: +39 065994.3412 Email: maddalena.barba@gmail.com</p>
<b>National programme</b>	
<b>Funding commitment</b>	0.250 Mio. €
<b>Anticipated number of fundable project partners</b>	1-2
<b>Maximum funding per grant awarded to a project partner</b>	€
<b>Eligibility of projects</b>	
<b>Eligibility of a partner as a beneficiary institution</b>	
<b>Eligibility of principal investigator or other research team member</b>	
<b>Eligibility of costs, types and their caps</b>	
<b>National phase</b>	
<b>Further guidance</b>	

<b>Country</b>	<b>LATVIA</b>
<b>Funding organisation</b>	<a href="#">Latvian Academy of Sciences</a>
<b>National contact persons</b>	<p><b>Dr. Maija BUNDULE</b>  <a href="mailto:maija.bundule@iza.lv">maija.bundule@iza.lv</a>  +371 67227790</p> <p><b>Dr. Uldis BERKIS</b>  <a href="mailto:uberkis@latnet.lv">uberkis@latnet.lv</a>  +371 67409242</p> <p>Latvian Academy of Sciences  1 Akademijas laukums  Riga, LV-1050, Latvia</p>
<b>National programme</b>	Support is provided according to Provisions Nr 414, 19.06.2012 of the Latvian Cabinet of Ministers <a href="http://www.likumi.lv/doc.php?id=249571">http://www.likumi.lv/doc.php?id=249571</a> Limitations and requirements of these provisions apply without exceptions.
<b>Funding commitment</b>	300.000 €
<b>Anticipated number of fundable project partners</b>	1-2
<b>Maximum funding per grant awarded to a project partner</b>	210 TEUR (ca 70 TEUR / year)
<b>Eligibility of projects</b>	The projects should correspond to the priorities of the TRANSCAN Call. Duration of the project - up to 3 years. The activities must correspond to “research” according to Latvian law.
<b>Eligibility of a partner as a beneficiary institution</b>	Legal bodies: universities, state research institutes, other research institutions: should be listed in the Latvian register of research institutions. Enterprises entered into the Latvian Commercial registry are eligible, assumed they are eligible to do the specific research and can prove it. Limitations of EU legislation apply (R 651/2014) together with financial reporting requirements. None of the supported activities should be subject to state aid scrutiny.
<b>Eligibility of principal investigator or other research team member</b>	Principal investigator – researcher holding doctoral degree and experienced in the field related to the project thematic. Other research team members - researchers, physicians, technicians, assistants and supporting staff.
<b>Eligibility of costs, types and their caps</b>	Project eligible costs are as follows: <b>For the research project:</b> <ol style="list-style-type: none"> <li>1. Personnel costs (researchers, technicians and other supporting staff to the extent employed on the research project) and relevant taxes,</li> <li>2. Other direct costs such as consumables, equipment (only depreciation costs), reagents, animals etc.,</li> <li>3. Subcontracting (up to 25% of total direct costs), with justification, includes also external patents and licenses and all external</li> </ol>

	<p>services,</p> <ol style="list-style-type: none"> <li>4. Travels and allowances,</li> <li>5. Overheads can reach a maximum of 20% of the direct project costs, and must be justified if they exceed 10%.</li> </ol> <p><b>For the capacity building and training activities:</b></p> <ol style="list-style-type: none"> <li>1. Short term training related to the project needs – covering only direct travel costs.</li> </ol> <p>Core activities cannot be subcontracted.</p>
<b>National phase</b>	
<b>Further guidance</b>	

<b>Country</b>	<b>THE NETHERLANDS</b>	
<b>Funding organisation</b>	<a href="#">Dutch Cancer Society (DCS / KWF Kankerbestrijding)</a>	<a href="#">The Netherlands Organisation for Health Research and Development (ZonMw)</a>
<b>National contact persons</b>	<b>Dr. Merel Hoozemans:</b> tel: +31-20-5700500; email: <a href="mailto:mhoozemans@kwf.nl">mhoozemans@kwf.nl</a>	<b>Drs. Erica Hackenitz:</b> tel +31-70-349 5159, e-mail: <a href="mailto:Hackenitz@zonmw.nl">Hackenitz@zonmw.nl</a>
<b>National programme</b>		
<b>Funding commitment</b>	1 Mio €	0.3 Mio € (In addition to the DCS / KWF Kankerbestrijding contribution)
<b>Anticipated number of fundable project partners</b>	3- 4	1
<b>Maximum funding per grant awarded to a project partner</b>	~ 0.3 M€ (including funding for capacity building and training activities)	
<b>Eligibility of projects</b>	Please refer to the call text.	
<b>Eligibility of a partner as a beneficiary institution</b>	Please refer to the general research grant conditions of KWF Kankerbestrijding on our website	As for DCS / KWF Kankerbestrijding
<b>Eligibility of principal investigator or other research team member</b>	Please refer to the general research grant conditions of KWF Kankerbestrijding on our website	As for DCS / KWF Kankerbestrijding
<b>Eligibility of costs, types and their caps</b>	<b>For the research project as well as for the capacity building and training activities:</b> Please refer to the general research grant conditions of KWF Kankerbestrijding on our website. NB. Overhead costs are not eligible for funding.	As for DCS / KWF Kankerbestrijding
<b>National phase</b>		
<b>Further guidance</b>	The official call announcement will be published on the KWF Kankerbestrijding website ( <a href="http://www.kwf.nl">www.kwf.nl</a> ); applicants are strongly advised to Contact the national contact persons.	The official call announcement will be published in the Mediator and on the ZonMw web site. Applicants are strongly advised to contact one of the national contact persons: Merel Hoozemans or Erica Hackenitz

<b>Country</b>	<b>NORWAY</b>	
<b>Funding organisation</b>	The Research Council of Norway (RCN)	Norwegian Cancer Society (NCS)
<b>National contact persons</b>	<b>For RCN:</b>  <b>Karianne Solaas</b> , <a href="mailto:kso@rcn.no">kso@rcn.no</a>  <b>Henrietta Blankson</b> , <a href="mailto:hbl@rcn.no">hbl@rcn.no</a>	<b>For NCS:</b>  <b>Nina Anensen</b> , <a href="mailto:nina.anensen@kreftforeningen.no">nina.anensen@kreftforeningen.no</a>
<b>National programme</b>	<b>For RCN:</b> Publicly-initiated Clinical Cancer Studies (KREFT)	-
<b>Funding commitment</b>	0.5 Mio €	0.5 Mio €
<b>Anticipated number of fundable project partners</b>	3-5	
<b>Maximum funding per grant awarded to a project partner</b>	300.000 €	
<b>Eligibility of projects</b>	Translational studies allowing a rapid implementation into public health-related decisions or into the clinic are encouraged	
<b>Eligibility of a partner as a beneficiary institution</b>	Norwegian universities, university colleges, hospitals, independent research institutes and other publicly funded research groups. Private industry is not eligible.	
<b>Eligibility of principal investigator or other research team member</b>	The project manager should have completed a doctoral degree or have corresponding qualifications.	
<b>Eligibility of costs, types and their caps</b>	<b>For the research project:</b> Payroll expenses, grants/fellowships, procurement of R&D services, consumables, network measures  <b>For the capacity building activities:</b> Salary of temporary staff with a specific expertise, short term training, PhD, Post-doctoral fellowship, Exchange programme  Indirect costs/overhead will be covered by the Research Council of Norway.	
<b>National phase</b>	-	
<b>Further guidance</b>	-	

<b>Country</b>	<b>POLAND</b>
<b>Funding organisation</b>	National Centre for Research and Development <a href="http://www.ncbir.pl">www.ncbir.pl</a>
<b>National contact persons</b>	<b>Mr. Marcin CHMIELEWSKI</b> National Centre for Research and Development (NCBiR) Section for Research Projects BIOMED Tel: +48 22 24 42 858 (109) E-mail: <a href="mailto:m.chmielewski@ncbir.pl">m.chmielewski@ncbir.pl</a>
<b>National programme</b>	National Scientific Research Programme ( <i>Krajowy Program Badań</i> )
<b>Funding commitment</b>	0.5 Mio €
<b>Anticipated number of fundable project partners</b>	1-2
<b>Maximum funding per grant awarded to a project partner</b>	The NCBiR does not have a maximum funding per grant. The amount depends on the scientific needs and justification for the budget.
<b>Eligibility of projects</b>	All proposals must be aligned with National regulations, inter alia: <ul style="list-style-type: none"> <li>• The Act of 30 April 2010 on <b>the Principles of Financing Science</b>, published in Journal of Laws No. 96 item 615, 2010;</li> <li>• The Act of 30 April 2010 on <b>the National Centre for Research and Development</b>, published in Journal of Laws No. 96 item 616, 2010;</li> <li>• The Regulation of the Minister of Science and Higher Education of 28 October 2010 on criteria and rules on <b>granting state aid and “de minimis” aid</b> by the National Centre for Research and Development, published in Journal of Laws No. 215 item 1411, 2010.</li> </ul>
<b>Eligibility of a partner as a beneficiary institution</b>	According to The Act of 30 April 2010 on <b>the National Centre for Research and Development</b> following entities are eligible to apply, i.a.: <ul style="list-style-type: none"> <li>• Scientific institution;</li> <li>• Scientific consortia;</li> <li>• Scientific network;</li> <li>• Industrial Scientific Centre;</li> <li>• Scientific units of the Polish Academy of Sciences;</li> <li>• Legal entities with a registered seat in Poland;</li> <li>• Enterprises having the status of R&amp;D centre;</li> <li>• Enterprises conducting R&amp;D activity in other than aforementioned organizational form.</li> </ul>
<b>Eligibility of principal investigator or other research team member</b>	The cost of scholarship is not eligible.

<p><b>Eligibility of costs, types and their caps</b></p>	<p>Eligible costs i.a: Personnel, consumables, subcontracts, equipment, travel and subsistence, overhead, documentation, materials (see <i>guide for applicants</i>: <a href="http://www.ncbir.pl">www.ncbir.pl</a>)</p> <p>The cost of training is eligible up to 6 months.</p> <p>The cost of scholarship is not eligible.</p> <p>The maximum rate of support for research organizations is 100% of total costs (for all type of R&amp;D); for SEs : 100% for fundamental research, max. 80% for Industrial research and max. 60% for Experimental Development of total costs; for Mes: 100% for fundamental research, max. 75% for Industrial research, max. 50% - for Experimental Development; for LE's: 100% for fundamental research, max. - 65% for Industrial research and max. 40% for Experimental Development.</p>
<p><b>National phase</b></p>	<p>Polish Participants will be informed and invited to submit Polish proposal once the international evaluation and the ranking list has been established.</p>
<p><b>Further guidance</b></p>	<ul style="list-style-type: none"> <li>• The Act of 30 April 2010 on <b>the Principles of Financing Science</b>, published in Journal of Laws No. 96 item 615, 2010;</li> <li>• The Act of 30 April 2010 on <b>the National Centre for Research and Development</b>, published in Journal of Laws No. 96 item 616, 2010;</li> <li>• The Regulation of the Minister of Science and Higher Education of 28 October 2010 on criteria and rules on <b>granting state aid and “de minimis” aid</b> by the National Centre for Research and Development, published in Journal of Laws No. 215 item 1411, 2010.</li> </ul> <p>All eligible entities, invited to submit Polish proposal are obliged to use the rate of exchange of The European Central Bank dated on the day of opening the call.</p>

<b>Country</b>	<b>PORTUGAL</b>
<b>Funding organisation</b>	<a href="#">Foundation for Science and Technology (Fundação para a Ciência e a Tecnologia – FCT)</a>
<b>National contact persons</b>	<b>Marta Abrantes</b> +351 213 911596 <a href="mailto:marta.abrantes@fct.pt">marta.abrantes@fct.pt</a>
<b>National programme</b>	
<b>Funding commitment</b>	0.325 Mio €
<b>Anticipated number of fundable project partners</b>	1-2
<b>Maximum funding per grant awarded to a project partner</b>	325.000 € (Up to <b>200,000</b> € if the Applicant is the transnational project consortium coordinator. Up to <b>125,000</b> € if the Applicant is NOT the transnational project consortium coordinator).
<b>Eligibility of projects</b>	All proposals must be aligned with National regulations.
<b>Eligibility of a partner as a beneficiary institution</b>	National regulations apply.
<b>Eligibility of principal investigator or other research team member</b>	National regulations apply.
<b>Eligibility of costs, types and their caps</b>	<b>For the research project as well as for the capacity building and training activities:</b> National regulations apply.
<b>National phase</b>	In the pre-proposal and in the full proposal phase no national application is needed, the electronic transnational application to the central TRANSCAN Joint Call Secretariat is sufficient. The national application by the Portuguese primary investigator to the Foundation of Science and Technology (FCT) will be mandatory for Portuguese participants, participating in those transnational projects that will be proposed for funding by the TRANSCAN Call Steering Committee.
<b>Further guidance</b>	<a href="http://www.fct.pt/apoios/projectos/regulamento.phtml.en">http://www.fct.pt/apoios/projectos/regulamento.phtml.en</a>

<b>Country</b>	<b>SLOVAK REPUBLIC</b>
<b>Funding organisation</b>	Slovak Academy of Sciences <a href="http://www.sav.sk">http://www.sav.sk</a>
<b>National contact persons</b>	<b>Mr. Jan BARANCIK</b> , PhD Department for International Cooperation of SAS, Slovak Academy of Sciences, Štefánikova 49 814 38 - Bratislava, Slovak Republic Tel: +421 2 5751 0137 E-mail: <a href="mailto:barancik@up.upsav.sk">barancik@up.upsav.sk</a>
<b>National programme</b>	Research in the field of biological, medical and pharmaceutical sciences
<b>Funding commitment</b>	0.21 Mio €
<b>Anticipated number of fundable project partners</b>	1-2
<b>Maximum funding per grant awarded to a project partner</b>	up to 105 000 € for 3 year project period for an applicant from the Slovak Academy of Sciences, applicants from other Slovak R & D centres should cover the project costs from their own sources
<b>Eligibility of projects</b>	<ul style="list-style-type: none"> <li>■ 3 year transnational projects with 3 or more eligible project consortium partners and from at least 3 different TRANSCAN joint transnational call 2011 funding countries</li> <li>■ Translational projects are encouraged</li> </ul>
<b>Eligibility of a partner as a beneficiary institution</b>	Research institutes of SAS
<b>Eligibility of principal investigator or other research team member</b>	<ul style="list-style-type: none"> <li>■ Each researcher of the core research team of a project consortium Slovak partner (other than the Principal Investigator) must have a job contract with or a fellowship with such a Slovak project partner, lasting until the end of the project or beyond</li> <li>■ The principal Investigator of the research team of a project consortium Slovak partner must be a senior researcher having a job contract with such a project partner, lasting until the end of the granted project or beyond.</li> </ul>
<b>Eligibility of costs, types and their caps</b>	Direct costs (DC) : Personnel (max. 15% of DC), Consumables, Equipment (max. 40% of DC) and Travel costs will be as eligible costs. Indirect costs (IC - overheads): max. 20 % of DC. Total eligible costs = DC + IC Training costs shall not be defined as a separate category, but included in other costs items.
<b>National phase</b>	Submission of the proposal at a national level will be carried out once the international evaluation and the ranking list have been performed and endorsed by the Call steering committee (CSC) and the Slovak project partner has been informed by the project consortium coordinator and invited by SAS to submit the proposal to it.

	The Presidium of SAS makes the final decision concerning the approval of funding (according to internal rules of SAS).
<b>Further guidance</b>	<a href="http://www.sav.sk/">http://www.sav.sk/</a> ; 133 Act of February 19, 2002 on the Slovak Academy of Sciences, Financial rules for awarding SAS grants for research projects in frame of ERA.Net Programme for research institutes of SAS Principles of allocation of funds for the institutes of SAS to support projects in the field of international scientific cooperation

<b>Country</b>	<b>SLOVENIA</b>
<b>Funding organisation</b>	Ministry of Higher Education, Science and Technology (MHEST) <a href="http://www.mvzt.gov.si/en/">http://www.mvzt.gov.si/en/</a>
<b>National contact persons</b>	<p><b>Ms. Kim TURK KRIZANEC</b> Science Policy Division Science and Technology Directorate Kotnikova 38, 1000 Ljubljana – Slovenia Tel: +386 1 4784705 E-mail: <a href="mailto:kim.turk-krizanec@gov.si">kim.turk-krizanec@gov.si</a></p> <p>Mr. Luka <b>ZIVIC</b> E-mail: <a href="mailto:luka.zivic@gov.si">luka.zivic@gov.si</a></p>
<b>National programme</b>	Projects of international scientific cooperation
<b>Funding commitment</b>	0.45 Mio. €
<b>Anticipated number of fundable project partners</b>	3-6
<b>Maximum funding per grant awarded to a project partner</b>	70.000 €/ year if the Slovenian researchers participate as partners, 150.000 €/ year if a Slovenian researcher is the coordinator of the transnational project
<b>Eligibility of projects</b>	As in the international call text
<b>Eligibility of a partner as a beneficiary institution</b>	<p>Research organizations (universities, research institutes, SMEs etc.), defined as eligible in the national Research and Development Act (Official Gazette of the Republic of Slovenia No. 22/2006 (UPB-1), 61/2006 (ZDru-1), 112/2007 and 9/2011) are eligible to apply.</p> <p>All participating institutions have to be registered in the Slovenian Research Agency evidences of research institutions.</p>
<b>Eligibility of principal investigator or other research team member</b>	<p>The primary investigator has to fulfill the requirements for project leader as defined in Art. 29 of the national Research and Development Act (Official Gazette of the Republic of Slovenia No. 22/2006 (UPB-1), 61/2006 (ZDru-1), 112/2007 and 9/2011). The criteria are determined in the Rules on Determining the Fulfillment of Conditions for a Research Project Leader (Official Gazette of the Republic of Slovenia No.41/2009) - must have a PhD, internationally comparable research results in the last five years (COBISS data base)...</p> <p>All participating researchers have to be registered in the national Slovenian Research Agency evidences of researchers. Participating researchers must have available research hours.</p>
<b>Eligibility of costs, types and their caps</b>	<p>MHEST will fund the eligible costs of Slovenian partners for successful transnational collaboration in accordance with the Decree on criteria and standards for allocating resources for the implementation of the National Research and Development Program (Official Gazette of the Republic of Slovenia No. 74/2004, 32/2005, 26/2006, 80/2007 and 102/2009).</p> <p>Eligible costs are defined according to the Slovenian Research Agency's value of research hours for a project: Personnel, Material costs (including travel, equipment and subcontracting), Amortization, Training.</p> <p>Funding is subject to the availability of national funds in accordance with the Community Framework for State Aid for Research and</p>

	<p>Development and Innovation (<a href="http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2006:323:0001:0026:SL:PDF">http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2006:323:0001:0026:SL:PDF</a>) (<a href="http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2006:323:0001:0026:EN:PDF">http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2006:323:0001:0026:EN:PDF</a>).</p> <p>The funding quota of Slovenian participants can be up to 100 % for universities or research organisations. In the case of companies, the funding quota will be decided on a case-by-case basis depending on the size of the company, type of research/development, risk associated with the research activities, commercial perspective of exploitation, typically up to a range of max. 50 %. In the case of small and medium enterprises an additional bonus of 10-20 % funding quota can be awarded.</p>
<p><b>National phase</b></p>	<p>In the pre-proposal and in the full proposal phase no national application is needed, the electronic transnational application to the central TRANSCAN Joint Call Secretariat is sufficient. The applicants must however send MHEST a written statement declaring they have read and agree with the national eligibility criteria. The statement is available on the Ministry's webpage (<a href="http://www.mvzt.gov.si/si/javni_razpisi/">http://www.mvzt.gov.si/si/javni_razpisi/</a>) and must be sent to the national contact person in parallel to sending the pre-proposal application.</p> <p>The national application by the Slovenian primary investigator to the Ministry of Higher Education, Science and Technology will be mandatory for Slovenian participants, participating in those transnational projects that will be proposed for funding by the TRANSCAN Call Steering Committee.</p> <p>The rules and forms for transnational applications are available on the TRANSCAN web page, the rules and application forms for the national application are available on the Ministry's webpage (<a href="http://www.mvzt.gov.si/si/javni_razpisi/">http://www.mvzt.gov.si/si/javni_razpisi/</a>).</p>
<p><b>Further guidance</b></p>	<p>The official national call announcement will be published in the Official Gazette of Republic of Slovenia (Uradni list Reublike Slovenije) and on the MHEST website (LINK: <a href="http://www.mvzt.gov.si/si/javni_razpisi/">http://www.mvzt.gov.si/si/javni_razpisi/</a>).</p> <p>The applicants are strongly advised to contact the national contact persons.</p>

<b>Country</b>	<b>SPAIN</b>
<b>Funding organisation</b>	National Institute of Health Carlos III (Instituto de Salud Carlos III, ISCIII) <a href="http://www.isciii.es">www.isciii.es</a>
<b>National contact persons</b>	Instituto de Salud Carlos III Office of the Deputy Director of International Research Programmes and Institutional Relations - SG de Programas Internacionales de Investigación y Relaciones Institucionales (ISCIII-SGPIIRI) <b>Ana TARDÓN</b> . Email: <a href="mailto:atardon@externos.isciii.es">atardon@externos.isciii.es</a> ; Tel: (+34) 91 822 25 30 Monforte de Lemos, 3 E-28029 Madrid – Spain
<b>National programme</b>	Strategic Action for Health Research (AES / Acción Estratégica en Salud) <a href="http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-financiacion/convocatorias-ayudas-accion-estrategica-salud.shtml">www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-financiacion/convocatorias-ayudas-accion-estrategica-salud.shtml</a>
<b>Funding commitment</b>	up to 0.5 Mio. € (including overheads) <i>Funding by ISCIII is subject to the approval of the relevant annual appropriations by the Spanish Parliament</i>
<b>Anticipated number of fundable project partners</b>	3-5 research groups
<b>Maximum funding per grant awarded to a project partner</b>	Only one 3 year grant per fundable project partner: Only one 3-year grant per fundable project partner: <ul style="list-style-type: none"> <li>• up to 100,000 € (overheads included) per project partner (up to 150,000 € per project for the whole Spanish part funded by ISCIII in case more than one Spanish partner participates in the same proposal);</li> <li>• up to 150.000 € (overheads included) per project coordinator (up to 200.000 € for the whole Spanish part funded by ISCIII in case one Spanish eligible institution coordinates the project consortium).</li> </ul> <i>Funding by ISCIII is subject to the approval of the relevant annual appropriations by the Spanish Parliament</i>
<b>Eligibility of projects</b>	<ul style="list-style-type: none"> <li>• Only one application can be submitted per Spanish project partner: Additional submissions will be rejected</li> <li>• Researchers with ongoing TRANSCAN projects in 2016 will be discarded. Exceptions: when the Spanish project partner (PI) is the consortium coordinator. Compatibility regarding ongoing projects/parallel applications within the R+D+I Plan of Spain, European Union or International frameworks is subject to the specifications stated in the relevant calls</li> </ul>
<b>Eligibility of a partner as a beneficiary institution</b>	<b>Eligible organisations:</b> <ul style="list-style-type: none"> <li>- <b>Hospitals, primary health care or public health settings of the Spanish National Health System (SNS) with legal address in Spain</b> (These must be part of the SNS and manage research via a foundation, in accordance to the Spanish Act 50/2002, of December 26th (a copy of the foundation's statutes must be submitted))</li> <li>- <b>Public Research Centres</b> conducting investigation in <b>Oncology</b></li> <li>- Health Research Institutes (IIS) certified according to the RD 339/2004, of February 27<sup>th</sup> (managed via a foundation according to the Spanish Act 50/ 2002, of December 26<sup>th</sup>) and <b>only if the Spanish applicant is the consortium coordinator</b></li> <li>- <b>CIBERs</b> only if the Spanish applicant is the <b>consortium coordinator</b></li> </ul> <b>GENERAL REMARK:</b> Maximum number of projects partners asking for funding to ISCIII in the same project proposal from the same beneficiary institution is up to 2

<p><b>Eligibility of principal investigator or other research team member</b></p>	<p><b>Eligibility of PIs</b> and other research team members:</p> <ul style="list-style-type: none"> <li>• PI must be a senior researcher and have a contractual relationship with an eligible organisation</li> <li>• Research team members must have a contractual relationship/fellowship with an eligible organisation</li> </ul> <p><b>Excluded personnel as Principal Investigator (PI):</b></p> <ul style="list-style-type: none"> <li>• Those undergoing a Postgraduate training in Health Specialisation</li> <li>• Those currently undergoing research training (e.g. PhD students, or “Rio Hortega Programme”)</li> <li>• Research personnel contracted by a RETICS or a CONSOLIDER</li> <li>• Those undergoing Post-doctoral training (e.g. “Sara Borrell” or “Juan de la Cierva” contracts)</li> </ul>
<p><b>Eligibility of costs, types and their caps</b></p>	<p>Only expenses committed and invoices dated and charged within the legal frame of the Spanish grant provided by ISCIII</p> <p><b>Personnel:</b> : Hiring full-time or part-time technical manpower up to three years (other than core research team members) only in case the Spanish applicant is the project consortium coordinator</p> <ul style="list-style-type: none"> <li>• Excluded: Students or fellowships are not eligible</li> <li>• Prefixed bulk cost (salary + taxes + social security, etc.) per annual full-time contract:             <ul style="list-style-type: none"> <li>○ Technical expert, higher degree: €29,500.00</li> <li>○ Technical expert, medium degree: €24,500.00</li> <li>○ Technical expert, FP II: €20,500.00</li> </ul> </li> </ul> <p><b>Small Equipment:</b> up to €40,000.00 (up to €20,000.00 if the Spanish project partner is not the consortium coordinator)</p> <p><b>Consumables.</b></p> <p><b>Travel and allowance</b> just for the research team members:</p> <ul style="list-style-type: none"> <li>• If the Spanish partner is not the consortium coordinator: up to €6,000.00 (project meetings, presentation of results and presentation of field studies must be foreseen)</li> <li>• If the Spanish PI is the consortium coordinator: up to €10,000.00 can be dedicated to travel and allowance.</li> </ul> <p><b>Commissions:</b> subcontracting up to the 50% of awarded budget for direct cost. When appropriate, subcontracting with private (bio)companies and SMEs is encouraged</p> <p><b>Overheads</b> (ex officio): up to +21% of the Spanish National funds. Please make sure when estimating the project’s budget that you include 21% to the grant provided by ISCIII.</p>
<p><b>National phase</b></p>	<p>Spanish PIs invited to the second phase (full proposal stage) will be invited by ISCIII to submit the application to the National phase and only those recommended for funding by the Call Steering Committee may be funded. Once that European’s ranking list is endorsed, the Joint Call Secretariat will inform the consortium coordinator on the results, and project consortium coordinators shall then inform the interested partners</p>
<p><b>Mandatory acknowledgement</b></p>	<p>All publications/presentations arising from a TRANSCAN project funded by ISCIII must state “Award n° XX by ISCIII through AES and within Transcan-2 framework”, even after completion of the funding period</p>

<b>Country</b>	<b>SPAIN</b>
<b>Funding organisation</b>	The Foundation for the support of the Applied Scientific Research and Technology in Asturias (FICYT) <a href="http://www.ficyt.es">http://www.ficyt.es</a>
<b>Regional contact persons</b>	<b>Ms. Inés REY HIDALGO</b> Tel: +34 985 20 74 34 E-mail: <a href="mailto:inesrey@ficyt.es">inesrey@ficyt.es</a>
<b>Regional programme</b>	Regional Programme for funding Science, Technology and Innovation
<b>Funding commitment</b>	0.3 Mio. €
<b>Anticipated number of fundable project partners</b>	4-5 TRANSCAN-2 transnational project partners
<b>Maximum funding per grant awarded to a project partner</b>	<p>Only one three year grant per fundable project partner:</p> <ul style="list-style-type: none"> <li>Up to 150,000 € (overheads included) per project coordinator (up to 200.000 € per project for the whole Asturian part funded by the Regional Ministry in case one Asturian eligible institution coordinates the project consortium);</li> <li>Up to 100,000 € (overheads included) per project partner (up to 150.000 € per project for the whole Asturian part funded by the Regional Ministry in case more than one Asturian partner participates in the same proposal).</li> </ul> <p><i>Funding by FICYT is subject to the approval of the relevant annual appropriations by the Regional Parliament in Asturias</i></p>
<b>Eligibility of projects</b>	<ul style="list-style-type: none"> <li>Transnational projects with 4 or more eligible project consortium partners and from at least 4 different TRANSCAN-2 joint transnational call 2014 funding countries.</li> <li>Minimum duration of the project: 12 months for industrial research / 9 months for experimental development.</li> <li>Maximum duration of the project: 36 months.</li> <li>Industry must demonstrate incentive effect of the aid.</li> </ul>
<b>Eligibility of a partner as a beneficiary institution</b>	Applications must be submitted by entities located in Asturias or, in case of companies, with a production center in Asturias.
<b>Eligibility of principal investigator or other research team member</b>	There will be a contact person taking part in the project to act as intermediary with the funding agency.
<b>Eligibility of costs, types and their caps</b>	<ul style="list-style-type: none"> <li>Expenses can only be committed and invoices charged with dates of each year in which the Asturian aid is granted</li> <li>Own staff: only that employees dedicated to the research project submitted to TRANSCAN-2 international call.</li> <li>Equipments: depreciation costs.</li> <li>Consumables.</li> <li>Subcontracts: up to 50% of the direct costs of the regional project.</li> <li>Other costs: travels, accommodation costs and allowances (only for staff appearing in the Personnel area of the proposal that directly takes part in the project); patenting costs; audit costs.</li> <li>Overheads: up to 10% of the Regional funds over the direct costs of the project.</li> </ul>

<b>Regional phase</b>	The submission of the proposal at regional level will be carried out once the international evaluation and the ranking list have been performed and endorsed by the Call Steering Committee (CSC) and the Spanish project partner IP has been informed by the project consortium coordinator and invited by FICYT to submit the proposal to it (at least at pre-proposal phase).
<b>Further guidance</b>	All applicants must comply with all the Regulations applicable to public funding at European, National and Regional level, and with all those Regulations indicated in the Regional Regulatory Bases and calls.

<b>Country</b>	<b>TAIWAN</b>
<b>Funding organisation</b>	Ministry of Science and Technology (MOST) <a href="http://www.most.gov.tw">http://www.most.gov.tw</a>
<b>National contact persons</b>	<b>Dr. Louis CHEN</b> Ministry of Science and Technology (Taiwan) Tel:+886-2-2737-7959 E-mail: <a href="mailto:ymchen@most.gov.tw">ymchen@most.gov.tw</a>
<b>National programme</b>	
<b>Funding commitment</b>	1 Mio. €
<b>Anticipated number of fundable project partners</b>	4-5
<b>Maximum funding per grant awarded to a project partner</b>	NTD 3Mio/Year (roughly €70,000/Year)
<b>Eligibility of projects</b>	The standard funding policy and eligibility rules set by the Ministry of Science and Technology applied.
<b>Eligibility of a partner as a beneficiary institution</b>	All research institutes, universities, hospitals, public organisations in Taiwan endorsed by the Ministry of Science and Technology as beneficiary institution.
<b>Eligibility of principal investigator or other research team member</b>	The standard funding policy and eligibility rules set by the Ministry of Science and Technology applied.
<b>Eligibility of costs, types and their caps</b>	Personnel, Consumables, Hosting expenses for foreign researchers, Travel expenses for international destinations-joint research & overseas studies
<b>National phase</b>	No official national application is needed in the pre-proposal or full proposal phase. But must notify the national contact person in the Ministry of Science and Technology of your submission to the TRANSCAN-2 joint transnational call via email, together with your application as an attachment.  A formal proposal must be submitted electronically via the Ministry's web submission portal together with an official missive sent from your institution, submission should be done after the joint TRANSCAN JTC 2014 peer review has been completed and the final (scientific) ranking list has been performed and endorsed by the Call Steering Committee. The submitted proposal will formally be granted by the Ministry of Science and Technology after an administrative and scientific processing.
<b>Further guidance</b>	Refer to the official announcement by the Ministry of Science and Technology for more information ( <a href="http://www.most.gov.tw/">http://www.most.gov.tw/</a> )

<b>Country</b>	<b>TURKEY</b>
<b>Funding organisation</b>	TUBITAK The Scientific and Technological Research Council of Turkey <a href="http://www.tubitak.gov.tr/">http://www.tubitak.gov.tr/</a>
<b>National contact persons</b>	<b>Ms. Melike SEVİMLİ</b> TÜBİTAK Tel: + 90 312 468 53 00 / 1976 E-mail: <a href="mailto:ncphealth@tubitak.gov.tr">ncphealth@tubitak.gov.tr</a>  <b>Ms. Ayşe Özge Gözay</b> TÜBİTAK Tel: + 90 312 468 53 00 / 1007 E-mail: <a href="mailto:ozge.gozay@tubitak.gov.tr">ozge.gozay@tubitak.gov.tr</a>
<b>National programme</b>	The Support Programme for Scientific and Technological Research Projects (1001)
<b>Funding commitment</b>	0.8 Mio. €
<b>Anticipated number of fundable project partners</b>	4 -5
<b>Maximum funding per grant awarded to a project partner</b>	Maximum funding per grant is 120.000 TL / year which is approximately 48.000 EUR / year (for 3 years maximum funding per grant is 360.000 TL which is approximately 144.000 EUR)
<b>Eligibility of projects</b>	All necessary documents and eligibility criteria can be checked via TUBITAK's web page on the national programme: <a href="http://www.tubitak.gov.tr/sid/367/pid/364/cid/9907/index.htm">http://www.tubitak.gov.tr/sid/367/pid/364/cid/9907/index.htm</a>
<b>Eligibility of a partner as a beneficiary institution</b>	Legal body: university, university hospital, public research institutes, industry
<b>Eligibility of principal investigator or other research team member</b>	Principal investigators from universities and university hospitals should at least have a PhD degree. Principal investigators from public research institutes and industry should at least have a university degree.  There are other requirements related to principal investigator and other research team members. This information should be checked thoroughly by the Turkish partner from the web site <a href="http://www.tubitak.gov.tr/sid/367/pid/364/cid/9907/index.htm">http://www.tubitak.gov.tr/sid/367/pid/364/cid/9907/index.htm</a> before organising the research team.
<b>Eligibility of costs, types and their caps</b>	Personnel, consumables, animals, subcontracts, equipment, travel, documentation.

<b>National phase</b>	<ul style="list-style-type: none"><li>• During the international submission phase, national submission will not be required.</li><li>• Submission of the proposal at the national level will be required as soon as the funded projects list announced after the international evaluation</li><li>• <b><u>Letter of Applications for ECA</u></b> should be submitted to TUBITAK in parallel to the international submission.</li><li>• <b><u>Original version of the “Ethics Committee Approvals - ECA”</u></b> should be submitted for the projects in which ECA is needed during the national submission.</li></ul>
<b>Further guidance</b>	Further information should be checked via TUBITAK’s web page on the national programme: <a href="http://www.tubitak.gov.tr/sid/367/pid/364/cid/9907/index.htm">http://www.tubitak.gov.tr/sid/367/pid/364/cid/9907/index.htm</a>